Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

STipe Therapeutics (DK)

STipe Therapeutics is a privately held biotechnology company with a vision to become a leader in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The Company was spun out from Aarhus University, Denmark in 2018 with the support of a PreSeed Grant from the Novo Nordisk Foundation and subsequently taking part in the Creation House program, including a convertible loan, from BioInnovation Institute (the Novo Nordisk Foundation's Biotech Incubator initiative). This was followed by an EUR 20 million in a Series A financing in September 2019. The round was co-led by Arix Bioscience plc and Novo Holdings A/S who were joined by Wellington Partners Life Science V Fund and Sunstone Life Science Ventures A/S. *

 

Period Start 2018-01-01 established (s-off)
  Predecessor Aarhus University
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 drug development
Person Person Olesen, Claus Elsborg (STipe Therapeutics 201909 CEO)
     
Region Region Denmark_oo
  Country Denmark
  City n. a. 
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Arix Bioscience plc. (9/30/19). "Press Release: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics". London.
     
   
Record changed: 2020-08-04

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for STipe Therapeutics (DK)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px




» top